Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT00130897. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A SU011248 Expanded Access Protocol For Systemic Therapy Of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation In Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
Study identification
- NCT ID
- NCT00130897
- Recruitment status
- Approved For Marketing
- Study type
- Expanded access
- Phase
- Not listed
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- Sutent Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2005
- Primary completion
- Oct 31, 2011
- Completion
- Oct 31, 2011
- Last update posted
- Mar 8, 2012
2005 – 2011
United States locations
- U.S. sites
- 53
- U.S. states
- 28
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Scottsdale | Arizona | 85260 | — |
| Pfizer Investigational Site | San Francisco | California | 94115-2378 | — |
| Pfizer Investigational Site | San Francisco | California | 94115 | — |
| Pfizer Investigational Site | Aurora | Colorado | 80040-0510 | — |
| Pfizer Investigational Site | Norwalk | Connecticut | 06856 | — |
| Pfizer Investigational Site | Miami | Florida | 33176 | — |
| Pfizer Investigational Site | Ocala | Florida | 34474 | — |
| Pfizer Investigational Site | Tampa | Florida | 33612 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30309 | — |
| Pfizer Investigational Site | Maywood | Illinois | 60153 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46260-2082 | — |
| Pfizer Investigational Site | Council Bluffs | Iowa | 51503 | — |
| Pfizer Investigational Site | Covington | Louisiana | 70433 | — |
| Pfizer Investigational Site | Gretna | Louisiana | 70056 | — |
| Pfizer Investigational Site | Marrero | Louisiana | 70072 | — |
| Pfizer Investigational Site | Metairie | Louisiana | 70002 | — |
| Pfizer Investigational Site | Metairie | Louisiana | 70006 | — |
| Pfizer Investigational Site | New Orleans | Louisiana | 70115 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21287 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02114 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02115 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02215 | — |
| Pfizer Investigational Site | Detroit | Michigan | 48201 | — |
| Pfizer Investigational Site | Minneapolis | Minnesota | 55455 | — |
| Pfizer Investigational Site | Southaven | Mississippi | 38671 | — |
| Pfizer Investigational Site | Tupelo | Mississippi | 38801 | — |
| Pfizer Investigational Site | Columbia | Missouri | 65201 | — |
| Pfizer Investigational Site | Columbia | Missouri | 65203 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68198-7680 | — |
| Pfizer Investigational Site | New York | New York | 10021 | — |
| Pfizer Investigational Site | New York | New York | 10022 | — |
| Pfizer Investigational Site | The Bronx | New York | 10466 | — |
| Pfizer Investigational Site | Durham | North Carolina | 27710 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44195 | — |
| Pfizer Investigational Site | Norman | Oklahoma | 73071 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73102 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73109 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73112 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73120 | — |
| Pfizer Investigational Site | Tulsa | Oklahoma | 74104 | — |
| Pfizer Investigational Site | Tulsa | Oklahoma | 74136-1902 | — |
| Pfizer Investigational Site | Portland | Oregon | 97210 | — |
| Pfizer Investigational Site | Portland | Oregon | 97227 | — |
| Pfizer Investigational Site | Hershey | Pennsylvania | 17033-0850 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38104 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38120 | — |
| Pfizer Investigational Site | Dallas | Texas | 75246 | — |
| Pfizer Investigational Site | Salt Lake City | Utah | 84112 | — |
| Pfizer Investigational Site | Seattle | Washington | 98104 | — |
| Pfizer Investigational Site | Seattle | Washington | 98109 | — |
| Pfizer Investigational Site | Seattle | Washington | 98122 | — |
| Pfizer Investigational Site | Seattle | Washington | 98124 | — |
| Pfizer Investigational Site | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 218 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00130897, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 8, 2012 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00130897 live on ClinicalTrials.gov.